Literature DB >> 1678681

Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy.

C Donow1, M Pipeleers-Marichal, S Schröder, B Stamm, P U Heitz, G Klöppel.   

Abstract

Specimens from the pancreas and duodenum of 26 patients with sporadic Zollinger-Ellison syndrome (ZES) and 18 patients with multiple endocrine neoplasia type 1 (MEN-1) and hypergastrinemia (17 with ZES) were screened immunocytochemically for gastrinomas. Location, size, multicentricity, and malignancy of the gastrinomas were evaluated. The MEN-1 patients had gastrinomas in the duodenum (nine of 18), pancreas (one of 18), and periduodenal lymph nodes (two of 18). No gastrinoma was identified in six patients. Most duodenal gastrinomas were multiple (five of nine) and smaller than 0.6 cm (six of nine). Lymph node metastases were present in eight of 12 patients. All 26 patients with sporadic ZES had a solitary gastrinoma; 14 were found in the pancreas and had a diameter greater than 2 cm. Ten patients had a duodenal gastrinoma, two with a diameter less than 0.6 cm. In two patients, only periduodenal "lymph node gastrinomas" were detected. Eighteen of the sporadic gastrinomas were malignant. These results suggest that duodenal location and multicentricity of gastrinomas are associated with the MEN-1 syndrome, and solitary gastrinomas, either in the pancreas or the duodenum, are predominantly seen in sporadic ZES.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678681     DOI: 10.1002/1097-0142(19910915)68:6<1329::aid-cncr2820680624>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE).

Authors:  G Cadiot; G Bonnaud; R Lebtahi; L Sarda; P Ruszniewski; D Le Guludec; M Mignon
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  [Tumors of the endocrine pancreas].

Authors:  M Anlauf; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

Review 3.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 4.  [Neuroendocrine tumors of the gastrointestinal tract].

Authors:  G Klöppel
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

Review 5.  [Tumors of the endocrine pancreas].

Authors:  G Klöppel
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

6.  Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?

Authors:  Jeffrey A Norton; H Richard Alexander; Douglas L Fraker; David J Venzon; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

Review 7.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 8.  Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I.

Authors:  M Pipeleers-Marichal; C Donow; P U Heitz; G Klöppel
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

9.  Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome.

Authors:  N W Thompson; J Pasieka; A Fukuuchi
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

Review 10.  Giant gastrinoma in a child: case report and review.

Authors:  Subramanya Kattepura; Kanishka Das; Marjorie Mariam Ann Correa; Harshad Devarabhavi
Journal:  Pediatr Surg Int       Date:  2008-08-05       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.